Orchid Pharma Approves Revised FY26 Financials Post-Amalgamation
Orchid Pharma's Board approved revised FY26 standalone and consolidated financial results post-amalgamation with Dhanuka Laboratories, effective July 10, 2026. Standalone and consolidated net sales for FY26 were ₹1,23,277.84 lakhs. The company also completed the acquisition of Allecra Therapeutics assets, gaining full global ownership of Enmetazobactam.
The revision of financial results due to amalgamation and the completion of strategic acquisitions are material events that can impact the company's structure, ownership, and future prospects, warranting a medium impact assessment.
The announcement details the revision of financial results due to an amalgamation and provides financial figures. While the amalgamation and acquisitions are significant corporate actions, the financial performance itself does not show a significant positive or negative trend that would sway the sentiment strongly.
Orchid Pharma Limited announced the outcome of its Board Meeting held on August 14, 2026. The Board considered and approved the revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. These revisions were necessitated by the sanctioned scheme of amalgamation and arrangement between Dhanuka Laboratories Limited and Orchid Pharma Limited, effective from July 10, 2026, with an appointed date of April 01, 2024. The auditors have issued an unmodified opinion on the revised standalone financial results and a modified opinion on the revised consolidated financial results.
The company also reported its financial performance for the period. For the quarter ended March 31, 2026, standalone net sales were ₹36,832.71 lakhs. For the full financial year ended March 31, 2026, standalone net sales stood at ₹1,23,277.84 lakhs. Consolidated net sales for the quarter were also ₹36,832.71 lakhs, and for the full year, they were ₹1,23,277.84 lakhs.
Orchid Pharma also provided updates on its strategic acquisitions. The company successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany, and Allecra Therapeutics SAS, France, on October 29, 2025, and August 01, 2025, respectively. This consolidation gives Orchid Pharma 100% global ownership of Enmetazobactam (EXBLIFEP/Orblicef), marking the full repatriation of a novel antibiotic molecule discovered in India. Additionally, the company acquired 100% share capital of Weilchensee 1272. V V GmbH, Germany, now renamed Orchid Pharma Europe GmbH, effective July 30, 2025.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.